CompletedPhase 1NCT00802802
Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Carolyn Bolton, MBBChUAB, CIDRZ
- Intervention
- Efavirenz (EFV)(drug)
- Enrollment
- 67 target
- Eligibility
- All sexes
- Timeline
- 2010 – 2018
Study locations (7)
- Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India
- Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa
- Shandukani Research CRS, Johannesburg, Gauteng, South Africa
- Durban Paediatric HIV CRS, Durban, KwaZulu-Natal, South Africa
- Family Clinical Research Unit (FAM-CRU) CRS, Tygerberg Hills, Western Cape, South Africa
- MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda
- Harare Family Care CRS, Harare, Zimbabwe
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00802802 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- RECRUITINGPHASE3NCT05575518A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisStellah Mpagama
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine